Fermentalg
ALGAE.PA operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic solutions.
Business. ALGAE.PA is a biotechnology and medical research company operating within the healthcare diagnostics industry. The firm is headquartered in France and is primarily listed on the Euronext Paris exchange under the ticker ALGAE.PA. Specific details regarding its operating segments and geographic revenue mix are not available.
Analyst recommendations
2 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
ALGAE.PA is a biotechnology and medical research company operating within the healthcare diagnostics industry. The firm is headquartered in France and is primarily listed on the Euronext Paris exchange under the ticker ALGAE.PA. Specific details regarding its operating segments and geographic revenue mix are not available.
The company's capital structure is characterized by a debt-to-equity ratio of 0.2, indicating a relatively low reliance on debt financing. However, its liquidity position is assessed as low, with a current ratio of 1.96, suggesting limited short-term liquidity to cover obligations. The company's cash and equivalents amount to 6.62 million EUR, but this is offset by negative operating and free cash flows of -6.59 million EUR and -7.91 million EUR, respectively.
Profitability metrics are weak, with a return on equity of -37.48% and a return on assets of -25.9%, both significantly below industry norms for biotechnology and medical research firms. The company reported a net loss of 9.44 million EUR, with operating income also negative at -9.38 million EUR, indicating ongoing operational challenges.
Geographic and segment exposure is not explicitly detailed in the available data, but the company's revenue is concentrated in a single business line, healthcare diagnostics, with no disclosed geographic diversification. This lack of diversification may increase exposure to regional or sector-specific risks.
The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. However, the negative operating and free cash flows suggest a lack of current momentum in revenue generation or cost control. Analysts have assigned a mean price target of 0.72 EUR, with a median of 0.72 EUR, and a mean recommendation of 1.50, indicating a cautiously optimistic outlook.
Risk factors include a low liquidity rating and the absence of immediate filing-based dilution flags. The company's dilution potential is assessed as low, with no near-term pressure expected. However, the negative cash flows and operating losses may necessitate future financing, which could introduce dilution risk.
Recent events include the latest financial filing, which shows continued losses and negative cash flows. No recent earnings call transcripts or major regulatory filings are available to provide additional insight into the company's strategic direction or operational performance.
- ALGAE.PA is a healthcare diagnostics company with a focus on biotechnology and medical research.
- The company is currently unprofitable, with a return on equity of -37.48% and a return on assets of -25.9%.
- Liquidity is low, with a current ratio of 1.96 and negative operating and free cash flows.
- The company's capital structure is relatively conservative, with a debt-to-equity ratio of 0.2.
- Analysts have a cautiously optimistic outlook, with a mean price target of 0.72 EUR and a mean recommendation of 1.50.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,09 |
| Revenue | —no estimate | —no estimate | 20,0M EUR |
| Operating income | —no estimate | —no estimate | -6,8M EUR |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- ALGAE.PA Market data — financials · 2026-05-27
- Fermentalg SA Market data — analyst estimates · 2026-05-27
Ownership & reference
Leadership
- Philippe LavielleChairman of the Board, Chief Executive Officer